Can Brain Cancer Cells Be Converted Into Neurons?

The Deadliest Brain Cancer Has a New and Unexpected Enemy

Glioblastoma is, by almost every measure, a nightmare diagnosis. The most aggressive form of primary brain cancer, it carries a median survival time of just 15 to 18 months after diagnosis — and that number has barely shifted in decades, despite enormous investment in oncology research. Surgery is limited by anatomy. Chemotherapy is blunted by the blood-brain barrier. Radiation buys time but rarely wins the war. For most patients, the current standard of care is a holding action, not a cure.

So when a research team at UCLA published findings suggesting it might be possible to convert glioblastoma cancer cells directly into neuron-like brain cells, the scientific community took notice. Not because the idea is new — cellular reprogramming has been a live area of research for years — but because this particular approach showed something genuinely different: a two-step treatment combining radiation with a naturally occurring molecule that seemed to nudge cancer cells away from malignancy and toward healthy neuronal identity. The implications, if the science holds up at human scale, would be profound.

This article unpacks what that research actually found, why glioblastoma is so uniquely resistant to treatment, what the biology of cellular reprogramming involves, and where the science still needs to go before this becomes anything more than a promising preclinical result.

Why Glioblastoma Is So Hard to Treat

To understand why the UCLA findings matter, you first have to appreciate just how hostile glioblastoma is as a therapeutic target. Unlike many cancers that form discrete, removable masses in accessible parts of the body, glioblastoma grows within the brain itself — an organ housed inside a rigid skull, densely packed with irreplaceable tissue that controls everything from memory and speech to movement and personality.

Surgeons can remove the visible tumour, but glioblastoma cells are notorious for infiltrating surrounding tissue in tendrils that no scalpel can chase without causing catastrophic damage. Leaving cells behind is almost inevitable.

Chemotherapy faces a different problem. The blood-brain barrier — a tightly regulated layer of specialised cells lining the brain's blood vessels — evolved to protect the brain from pathogens, toxins, and large molecules in the bloodstream. It does its job almost too well. Most chemotherapy drugs are too large or chemically incompatible to cross it in meaningful concentrations. The handful that do, like temozolomide, are useful but insufficient on their own.

Radiation can penetrate bone and tissue, and it is effective at damaging the DNA of rapidly dividing cancer cells. But it also damages healthy brain tissue. There is a ceiling on how much radiation you can deliver before the treatment becomes as destructive as the disease. Despite all three modalities working in concert, glioblastoma almost always recurs. The cells that survive are often more resilient than the ones that were killed.

The Biology Behind Turning Cancer Cells Into Brain Cells

To understand the UCLA approach, it helps to trace glioblastoma back to its cellular origins. The brain develops from neural stem cells — undifferentiated precursor cells that, under the right molecular conditions, differentiate into the two main cell types of the brain: neurons, which transmit electrical signals, and glial cells, which perform supportive and immune functions.

The key molecular signal in this differentiation process is cyclic adenosine monophosphate, or cAMP — a small signalling molecule that acts as a second messenger inside cells, relaying instructions that tell a stem cell what to become. During normal brain development, rising cAMP levels help push neural stem cells toward a neuronal identity.

Glioblastomas arise when glial cells, having already differentiated from stem cells, begin replicating uncontrollably. They are, in a sense, cells that have forgotten what they were supposed to be — or more precisely, cells that have been pushed by genetic mutations into a state of unchecked proliferation.

The theoretical logic of cellular reprogramming is elegant: if you could re-expose those cells to the right developmental signals, could you persuade them to stop behaving like cancer and start behaving like neurons again? It sounds almost implausibly simple, which is exactly why researchers have been cautiously chasing the idea for years.

What the UCLA Research Actually Found

The UCLA team's key insight came from prior work showing that glioblastoma cells that survive radiation treatment enter a more stem cell-like state — as if the stress of radiation partially resets their identity. Rather than viewing this as a problem, the researchers treated it as an opportunity. A cell in a stem-like state might be more susceptible to redifferentiation signals.

Their first experiment was direct: irradiate glioblastoma cells, then apply a cAMP analog — a synthetic molecule that mimics cAMP's signalling effects. The results were striking. The treated cells began to resemble neurons. They developed the characteristic elongated, branching morphology of neuronal cells. They began expressing proteins normally associated with neurons rather than glial cells. And critically, they stopped dividing at the cancerous rate they had been maintaining.

The problem with cAMP analogs is pharmacokinetic — they break down quickly in the body and cannot easily cross the blood-brain barrier, which means they would be largely useless in a clinical setting where you need the drug to actually reach the tumour. The team's solution was to stimulate the body's own cAMP production rather than delivering the molecule directly.

That is where forskolin enters the picture. Derived from the root of the Coleus forskohlii plant and long studied for its cardiovascular and metabolic effects, forskolin activates adenylyl cyclase — the enzyme that produces cAMP. Crucially, it has a longer half-life than cAMP analogs and can cross the blood-brain barrier. When the researchers applied radiation followed by forskolin to glioblastoma cells, the results mirrored those from the cAMP analog experiment: neuron-like morphology, neuronal protein expression, and suppressed cell division.

In mouse models with glioblastoma, the radiation-plus-forskolin combination extended average survival from 36 days to 129 days — more than three and a half times longer. That is a significant result in a preclinical model.

The Gap Between Mouse Results and Human Application

Here is where the honest accounting becomes important — and where anyone following this research should calibrate their expectations carefully.

When the team moved to a more clinically relevant model — implanting human glioblastoma cells into mouse brains and applying the same treatment — the results were positive but considerably less dramatic. Average survival increased from 34 to 48 days. The treatment reduced glioblastoma cell counts and some of the remaining cells showed signs of reverting to a pre-cancerous state. But the dramatic effect seen in the pure mouse model did not fully translate.

This gap is not unusual in cancer research, and it does not invalidate the approach. Human glioblastoma cells are biologically more complex and heterogeneous than mouse glioblastoma cells. Tumours in human patients contain multiple subpopulations of cells at different stages of differentiation and with different genetic mutations. A treatment that successfully nudges one subpopulation toward neuronal identity may do nothing to another.

Several variables remain to be optimised. Dosage is one — it is possible that higher or more precisely timed doses of forskolin would produce stronger effects. Combination is another. During normal brain development, cAMP does not act alone. It works alongside a network of other signalling molecules, growth factors, and transcription factors that collectively guide cell fate. A more sophisticated combination therapy that mimics this developmental environment more closely might be necessary to achieve full reprogramming in human tumour cells.

There is also the question of what a reprogrammed cell actually is. The cells in these experiments looked like neurons and expressed neuronal proteins, but the researchers were careful to note that they did not have full confirmation these were functionally equivalent to normal neurons. Whether reprogrammed cells could integrate into existing neural circuits, survive long-term, and perform useful functions — rather than simply being inert non-cancerous tissue — remains an open question.

What This Means for the Future of Glioblastoma Treatment

It would be a mistake to read this research as a cure on the horizon. It is not. But it is something genuinely new in a field that has been frustratingly static for patients and clinicians alike.

The concept of using differentiation therapy — compelling cancer cells to adopt a benign cellular identity — is not unique to glioblastoma. It is already deployed clinically in acute promyelocytic leukaemia, where all-trans retinoic acid induces cancerous immature blood cells to differentiate into normal mature cells. That treatment transformed a once-fatal diagnosis into one with a high survival rate. The challenge is that solid tumours, and brain tumours in particular, are far more complex environments than circulating blood cells.

The UCLA work also opens conceptual space for thinking about cancer treatment differently. Rather than asking only how to kill cancer cells, it asks how to change them. In glioblastoma, where killing every last cancer cell is essentially impossible given surgical and pharmacological constraints, the ability to render surviving cells non-malignant — or even functionally useful — could be transformative even if it falls short of complete elimination.

Forskolin itself has an interesting profile as a potential therapeutic molecule. It is relatively well-tolerated, has been studied in humans for other indications, and its blood-brain barrier penetration is a genuine clinical advantage. None of that guarantees it will work in glioblastoma patients, but it means the path from preclinical research to human trials is not starting from zero.

The more likely near-term development is a refined combination protocol — radiation, forskolin, and additional differentiation-promoting agents identified through further research — that moves into Phase I clinical trials to establish safety and preliminary efficacy in human patients. That process typically takes years. But the conceptual foundation has been laid.

A Different Way to Think About Treating Deadly Cancers

Glioblastoma will not be cured by a single mechanism. Its complexity, heterogeneity, and location guarantee that any successful long-term treatment will involve multiple complementary strategies. What the UCLA research contributes is a new strategic option — the possibility that cancer cells we cannot kill might still be neutralised by being transformed.

This matters beyond glioblastoma. Cellular reprogramming as a therapeutic strategy is being explored across oncology, regenerative medicine, and neuroscience. The tools are becoming more refined, the targets better understood, and the delivery mechanisms more sophisticated. The blood-brain barrier, long an obstacle, may increasingly become a solvable engineering problem rather than an absolute constraint.

For patients diagnosed with glioblastoma today, the standard of care remains what it has been for years: surgery, temozolomide, and radiation. The UCLA findings will not change that tomorrow. But they represent genuine scientific progress in a field that desperately needs it — a credible new direction backed by real data, even if that data still has a long way to travel before it reaches the clinic.

The idea of turning a patient's own cancer cells into functional brain tissue may sound like science fiction. Given what we now know about cellular plasticity and signalling, it is increasingly science in progress.

Frequently Asked Questions

What is glioblastoma and why is it so difficult to treat?

Glioblastoma is the most aggressive form of primary brain cancer, arising from glial cells in the brain. It is difficult to treat for several compounding reasons: the brain is enclosed within the skull, limiting surgical access; much of the surrounding tissue is critical and cannot be removed without serious neurological consequences; the blood-brain barrier prevents most chemotherapy drugs from reaching the tumour in effective concentrations; and glioblastoma cells infiltrate surrounding tissue in a way that makes complete surgical removal nearly impossible. The median survival after diagnosis is 15 to 18 months.

How does the UCLA treatment work to convert cancer cells into brain cells?

The treatment uses a two-step approach. First, radiation is applied to glioblastoma cells, which places surviving cancer cells into a more stem cell-like state. Second, a molecule called forskolin is introduced, which stimulates the production of cAMP — a signalling molecule involved in guiding neural stem cells to differentiate into neurons. Together, radiation and forskolin appear to nudge glioblastoma cells toward a neuron-like identity, causing them to adopt neuronal shapes, express neuronal proteins, and stop dividing at cancerous rates.

Why did the treatment work better in mice than with human cancer cells?

Mouse glioblastoma cells and human glioblastoma cells differ significantly in their biological complexity. Human tumours are highly heterogeneous, containing multiple subpopulations of cells with different genetic mutations and at different stages of differentiation. A treatment that successfully reprograms one subpopulation may have limited effect on others. The dosage and combination of agents may also need to be optimised for human biology. This kind of gap between mouse model results and human cell results is common in cancer research and represents a stage in development rather than a failure of the concept.

Is forskolin safe for humans, and could it be used in clinical trials?

Forskolin is a naturally occurring compound derived from the Coleus forskohlii plant and has been studied in humans for other purposes, including cardiovascular applications. It is generally considered relatively well-tolerated. Importantly for this application, it can cross the blood-brain barrier — a critical advantage over many drug candidates targeting brain tumours. While its safety profile is encouraging, demonstrating efficacy in human glioblastoma patients would require formal clinical trials. The current research is still at the preclinical stage, meaning human trials are likely still several years away.

Could this approach be applied to other types of cancer?

The concept of differentiation therapy — using molecular signals to force cancer cells into a benign or functional cellular identity — is not limited to glioblastoma. It is already used clinically in acute promyelocytic leukaemia, where a drug called all-trans retinoic acid causes immature cancerous blood cells to mature into normal cells. Researchers are exploring similar approaches in other cancer types. However, applying it to solid tumours like glioblastoma is considerably more complex due to tumour heterogeneity, the microenvironment surrounding the cancer cells, and the challenges of drug delivery to specific tissues.